Portopulmonary hypertension

Portopulmonary hypertension (PoPH) is a form of pulmonary hypertension (PH) that occurs in individuals with portal hypertension, often due to cirrhosis of the liver. It is defined by the presence of pulmonary arterial hypertension (PAH) in the setting of portal hypertension.

Epidemiology

PoPH is estimated to occur in approximately 5-10% of individuals with portal hypertension. The exact prevalence is unknown due to the lack of large-scale epidemiological studies. However, it is known that the condition is more common in individuals with advanced liver disease.

Pathophysiology

The pathophysiology of PoPH is complex and not fully understood. It is thought to involve an imbalance between vasoconstrictive and vasodilative mediators in the pulmonary circulation, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. This is often accompanied by vascular remodeling and thrombosis in situ.

Clinical Presentation

Patients with PoPH may present with symptoms of both portal hypertension and pulmonary hypertension. These can include shortness of breath, fatigue, syncope, and signs of right heart failure such as edema and ascites. In many cases, the symptoms of pulmonary hypertension may be masked by the underlying liver disease, making diagnosis challenging.

Diagnosis

The diagnosis of PoPH is made based on a combination of clinical findings, imaging studies, and hemodynamic measurements. Echocardiography is often the first step in the diagnostic process, followed by right heart catheterization to confirm the diagnosis and assess the severity of the disease.

Treatment

The treatment of PoPH involves managing the underlying liver disease, treating the pulmonary hypertension, and in some cases, liver transplantation. Medications used to treat pulmonary hypertension, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues, may also be used in the treatment of PoPH.

Prognosis

The prognosis of PoPH is generally poor, with a median survival of less than 3 years in untreated patients. However, with appropriate treatment, survival can be significantly improved.

Portopulmonary hypertension Resources
Latest articles Most recent articles Ongoing trials	Wikipedia